From the Editor's Desk …
Transarterial radioembolization (TARE) with Y90 microspheres is used worldwide to treat patients with hepatocellular carcinoma (HCC). In contrast with repeated chemoembolization, Y90-RE is usually designed as a single treatment that nevertheless demands a pre-treatment work-up. Such work-up includes injecting Tc-99m macroaggregated albumin (MAA) to estimate lung shunt fraction and lung dose. To find out if MAA scans could be eliminated from routine practice in early HCC, Gabr et al. reviewed the lung shunt fraction from 448 patients with early stage HCC (UNOS T1/T2 or Milan criteria) treated by TARE.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli Tags: From the Editor's Desk Source Type: research
More News: Cancer & Oncology | Carcinoma | Gastroenterology | Hepatocellular Carcinoma | Liver Cancer | PET Scan